Lancet:青少年时期接受CT扫描会增加患癌风险

2012-06-12 范泽玲 健康报

       英国一项新研究说,在青少年时期接受CT扫描会增加以后患癌症的风险,这说明医生在选择是否给青少年做CT扫描时应更仔细地权衡利弊。       英国纽卡斯尔大学等机构研究人员在新一期医学刊物《柳叶刀》上报告说,他们调查了约18万名英国人的医疗档案,这些人在1985年到2

       英国一项新研究说,在青少年时期接受CT扫描会增加以后患癌症的风险,这说明医生在选择是否给青少年做CT扫描时应更仔细地权衡利弊。

       英国纽卡斯尔大学等机构研究人员在新一期医学刊物《柳叶刀》上报告说,他们调查了约18万名英国人的医疗档案,这些人在1985年到2002年间接受了CT扫描,当时他们年龄都在22岁以下。分析显示,他们在第一次接受CT扫描后的10年中,出现癌症的风险高于正常水平,且患癌风险与接受多次扫描而累积的辐射剂量成正相关。相当于两到三次普通CT扫描所带来的辐射剂量,会导致患者出现大脑肿瘤或白血病的风险上升3倍。

       CT扫描的全称是计算机断层扫描,它利用射线穿透被测物体,再用计算机建立三维图像,帮助医生了解患者身体内部的情况。扫描中产生的辐射可能会对身体组织造成伤害,增加患癌症风险。

       研究人员说,这项研究通过直接证据显示,青少年时期接受CT扫描会增加患癌风险,但这一研究结果不是让患者拒绝CT扫描,而是提醒医生更好地衡量利弊。CT扫描在医学诊断中发挥着重要作用,如果患者病情确实有需要,还是应该接受CT扫描。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1827409, encodeId=337f182e4091e, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Dec 07 14:33:00 CST 2012, time=2012-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061322, encodeId=31a8206132279, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Wed Oct 17 23:33:00 CST 2012, time=2012-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413410, encodeId=178514134107e, content=<a href='/topic/show?id=3f225299942' target=_blank style='color:#2F92EE;'>#患癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52999, encryptionId=3f225299942, topicName=患癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b2c2959841, createdName=zzc2212, createdTime=Thu Jun 14 09:33:00 CST 2012, time=2012-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601306, encodeId=47681601306dd, content=<a href='/topic/show?id=5baa5299111' target=_blank style='color:#2F92EE;'>#患癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52991, encryptionId=5baa5299111, topicName=患癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=888f18872716, createdName=lq0307, createdTime=Thu Jun 14 09:33:00 CST 2012, time=2012-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618752, encodeId=f9461618e5234, content=<a href='/topic/show?id=aa2e5463db' target=_blank style='color:#2F92EE;'>#CT扫描#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5463, encryptionId=aa2e5463db, topicName=CT扫描)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed3819951332, createdName=ms6323715314570549, createdTime=Thu Jun 14 09:33:00 CST 2012, time=2012-06-14, status=1, ipAttribution=)]
    2012-12-07 howi
  2. [GetPortalCommentsPageByObjectIdResponse(id=1827409, encodeId=337f182e4091e, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Dec 07 14:33:00 CST 2012, time=2012-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061322, encodeId=31a8206132279, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Wed Oct 17 23:33:00 CST 2012, time=2012-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413410, encodeId=178514134107e, content=<a href='/topic/show?id=3f225299942' target=_blank style='color:#2F92EE;'>#患癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52999, encryptionId=3f225299942, topicName=患癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b2c2959841, createdName=zzc2212, createdTime=Thu Jun 14 09:33:00 CST 2012, time=2012-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601306, encodeId=47681601306dd, content=<a href='/topic/show?id=5baa5299111' target=_blank style='color:#2F92EE;'>#患癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52991, encryptionId=5baa5299111, topicName=患癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=888f18872716, createdName=lq0307, createdTime=Thu Jun 14 09:33:00 CST 2012, time=2012-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618752, encodeId=f9461618e5234, content=<a href='/topic/show?id=aa2e5463db' target=_blank style='color:#2F92EE;'>#CT扫描#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5463, encryptionId=aa2e5463db, topicName=CT扫描)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed3819951332, createdName=ms6323715314570549, createdTime=Thu Jun 14 09:33:00 CST 2012, time=2012-06-14, status=1, ipAttribution=)]
    2012-10-17 sjq027
  3. [GetPortalCommentsPageByObjectIdResponse(id=1827409, encodeId=337f182e4091e, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Dec 07 14:33:00 CST 2012, time=2012-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061322, encodeId=31a8206132279, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Wed Oct 17 23:33:00 CST 2012, time=2012-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413410, encodeId=178514134107e, content=<a href='/topic/show?id=3f225299942' target=_blank style='color:#2F92EE;'>#患癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52999, encryptionId=3f225299942, topicName=患癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b2c2959841, createdName=zzc2212, createdTime=Thu Jun 14 09:33:00 CST 2012, time=2012-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601306, encodeId=47681601306dd, content=<a href='/topic/show?id=5baa5299111' target=_blank style='color:#2F92EE;'>#患癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52991, encryptionId=5baa5299111, topicName=患癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=888f18872716, createdName=lq0307, createdTime=Thu Jun 14 09:33:00 CST 2012, time=2012-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618752, encodeId=f9461618e5234, content=<a href='/topic/show?id=aa2e5463db' target=_blank style='color:#2F92EE;'>#CT扫描#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5463, encryptionId=aa2e5463db, topicName=CT扫描)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed3819951332, createdName=ms6323715314570549, createdTime=Thu Jun 14 09:33:00 CST 2012, time=2012-06-14, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1827409, encodeId=337f182e4091e, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Dec 07 14:33:00 CST 2012, time=2012-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061322, encodeId=31a8206132279, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Wed Oct 17 23:33:00 CST 2012, time=2012-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413410, encodeId=178514134107e, content=<a href='/topic/show?id=3f225299942' target=_blank style='color:#2F92EE;'>#患癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52999, encryptionId=3f225299942, topicName=患癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b2c2959841, createdName=zzc2212, createdTime=Thu Jun 14 09:33:00 CST 2012, time=2012-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601306, encodeId=47681601306dd, content=<a href='/topic/show?id=5baa5299111' target=_blank style='color:#2F92EE;'>#患癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52991, encryptionId=5baa5299111, topicName=患癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=888f18872716, createdName=lq0307, createdTime=Thu Jun 14 09:33:00 CST 2012, time=2012-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618752, encodeId=f9461618e5234, content=<a href='/topic/show?id=aa2e5463db' target=_blank style='color:#2F92EE;'>#CT扫描#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5463, encryptionId=aa2e5463db, topicName=CT扫描)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed3819951332, createdName=ms6323715314570549, createdTime=Thu Jun 14 09:33:00 CST 2012, time=2012-06-14, status=1, ipAttribution=)]
    2012-06-14 lq0307
  5. [GetPortalCommentsPageByObjectIdResponse(id=1827409, encodeId=337f182e4091e, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Dec 07 14:33:00 CST 2012, time=2012-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061322, encodeId=31a8206132279, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Wed Oct 17 23:33:00 CST 2012, time=2012-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413410, encodeId=178514134107e, content=<a href='/topic/show?id=3f225299942' target=_blank style='color:#2F92EE;'>#患癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52999, encryptionId=3f225299942, topicName=患癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b2c2959841, createdName=zzc2212, createdTime=Thu Jun 14 09:33:00 CST 2012, time=2012-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601306, encodeId=47681601306dd, content=<a href='/topic/show?id=5baa5299111' target=_blank style='color:#2F92EE;'>#患癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52991, encryptionId=5baa5299111, topicName=患癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=888f18872716, createdName=lq0307, createdTime=Thu Jun 14 09:33:00 CST 2012, time=2012-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618752, encodeId=f9461618e5234, content=<a href='/topic/show?id=aa2e5463db' target=_blank style='color:#2F92EE;'>#CT扫描#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5463, encryptionId=aa2e5463db, topicName=CT扫描)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed3819951332, createdName=ms6323715314570549, createdTime=Thu Jun 14 09:33:00 CST 2012, time=2012-06-14, status=1, ipAttribution=)]